Cellulitis News and Research

Latest Cellulitis News and Research

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational agent for postmenopausal women with osteoporosis.

3 Apr 2017

New comprehensive study lists top personal health expenses in the U.S.

Just 20 conditions make up more than half of all spending on health care in the United States, according to a new comprehensive financial analysis that examines spending by diseases and injuries.

28 Dec 2016

Hospitals eliminate bedsore occurrence using early detection technology

Using technology adapted from NASA's Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating hospitals were able to eliminate the occurrence of new bedsores completely; an additional 3 hospitals achieved reductions ranging from 11% to 90%.

23 Dec 2016

Simple steps can improve survival of sepsis patients

Sepsis, commonly called blood poisoning, is a common affliction that can affect people of all ages. A series of simple measures tested at a Norwegian hospital can make a difference in successfully treating sepsis.

31 Aug 2016

Eczema can increase patients' risk of developing several other health conditions

When a patient is diagnosed with eczema, the diagnosis of another medical condition may not be far behind.

28 Jul 2016

Scientists discover new biological defense system against pathogenic microorganisms

For the first time in the world, a group of researchers discovered a human immune receptor, which detects the invasion of pathogenic microorganisms.

13 Jul 2016

Liposuction to manage lymphedema? An interview with Professor John Boyages

Lymphedema is persistent swelling of the arm and/or hand following biopsy or treatment of the axillary lymph nodes for patients with breast cancer. It is due to excess accumulation of protein‐rich fluid in body tissues.

4 May 2016

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).

22 Feb 2016

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan plc today announced the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil).

16 Feb 2016

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer that can be difficult to treat.

29 Oct 2015

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that one of its subsidiaries, Sinovac Dalian, has received approval to begin human clinical trials on its varicella vaccine candidate. The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration in January 2013.

26 Oct 2015

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Amgen today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion recommending that IMLYGIC (talimogene laherparepvec) be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

23 Oct 2015

Advanced pneumatic compression device reduces cellulitis episodes, saves money for lymphedema patients

Lymphedema patients saw a nearly 80 percent reduction in their cellulitis episodes just by using an advanced pneumatic compression device at home, according to a study in JAMA Dermatology co-authored by Vanderbilt University School of Nursing Professor Sheila Ridner, PhD, MSHSA, FAAN, and University of Minnesota School of Public Health Associate Professor Pinar Karaca-Mandic, PhD.

8 Oct 2015

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

2 Sep 2015

Hospital physicians rarely identify or address overweight/obesity in children

Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist.

6 Aug 2015

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

1 Jun 2015

Ebola outbreak emphasizes the importance of monitoring disease burden in developing countries

A study recently published in the Journal of the American Academy of Dermatology shows that for Ebola, measles, syphilis and many other conditions with skin manifestations the mortality rates are hundreds of times higher in developing countries than they are in developed countries.

16 Oct 2014

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant Gram-positive and Gram-negative pathogens, announced today that the United States Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) as well as Fast Track status designation to Nabriva's lead product lefamulin, for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

8 Oct 2014

Cellulitis News and Research

Latest Cellulitis News and Research

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

New comprehensive study lists top personal health expenses in the U.S.

Hospitals eliminate bedsore occurrence using early detection technology

Simple steps can improve survival of sepsis patients

Eczema can increase patients' risk of developing several other health conditions

Scientists discover new biological defense system against pathogenic microorganisms

Liposuction to manage lymphedema? An interview with Professor John Boyages

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck expand oncology clinical trial collaboration

Oncolytic (cancer-killing) viral therapy approved in the U.S. for use against late-stage melanoma

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Amgen's IMLYGIC receives positive opinion from CHMP for treatment of melanoma

Advanced pneumatic compression device reduces cellulitis episodes, saves money for lymphedema patients

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Hospital physicians rarely identify or address overweight/obesity in children

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Ebola outbreak emphasizes the importance of monitoring disease burden in developing countries

FDA grants QIDP and Fast Track designation to Nabriva's lefamulin for treatment of CABP, ABSSSI

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Cellulitis News and Research

Latest Cellulitis News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in